145 related articles for article (PubMed ID: 20351319)
41. Treatment outcomes of and prognostic factors for definitive radiotherapy with and without chemotherapy for Stage I/II nasal extranodal NK/T-cell lymphoma.
Yang CW; Wang CW; Hong RL; Tsai CL; Yao M; Tang JL; Lin CW; Cheng AL; Kuo SH
J Radiat Res; 2017 Jan; 58(1):114-122. PubMed ID: 27534792
[TBL] [Abstract][Full Text] [Related]
42. Treatment outcome of angiocentric T-cell and NK/T-cell lymphoma, nasal type: radiotherapy versus chemoradiotherapy.
Kim K; Chie EK; Kim CW; Kim IH; Park CI
Jpn J Clin Oncol; 2005 Jan; 35(1):1-5. PubMed ID: 15681596
[TBL] [Abstract][Full Text] [Related]
43. Variable clinical presentations of nasal and Waldeyer ring natural killer/T-cell lymphoma.
Li YX; Liu QF; Fang H; Qi SN; Wang H; Wang WH; Song YW; Lu J; Jin J; Wang SL; Liu YP; Lu N; Liu XF; Yu ZH
Clin Cancer Res; 2009 Apr; 15(8):2905-12. PubMed ID: 19318493
[TBL] [Abstract][Full Text] [Related]
44. Primary nasal natural killer/T-cell lymphoma presenting as simultaneous bilateral proptosis in a child.
Liu W; Shu Q; Ren J; Yin T; Wang Y; Chen X; Li L
Pediatr Hematol Oncol; 2012 Mar; 29(2):166-9. PubMed ID: 22292509
[No Abstract] [Full Text] [Related]
45. Radiotherapy combined with chemotherapy versus radiotherapy alone for early stage nasal natural killer/T-cell lymphoma: a meta-analysis.
Zhang B; Zhu F; Liu X; Zhao J; Li M; Li Y; Huang J; Zou L; Chang Q
J Chemother; 2016; 28(1):65-71. PubMed ID: 25971360
[TBL] [Abstract][Full Text] [Related]
46. Nasal NK/T-cell lymphoma: RT, CT, or both.
Tse E; Kwong YL
Blood; 2015 Sep; 126(12):1400-1. PubMed ID: 26384281
[TBL] [Abstract][Full Text] [Related]
47. [Prognostic analysis of patients with nasal-type NK/T-cell non-Hodgkin's lymphoma--a report of 93 cases].
Pan ZH; Huang HQ; Lin XB; Xia YF; Xia ZJ; Peng YL; Cai QQ; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2005 Dec; 24(12):1493-7. PubMed ID: 16351799
[TBL] [Abstract][Full Text] [Related]
48. Simultaneous chemoradiotherapy compared with radiotherapy alone after induction chemotherapy in inoperable stage IIIA or IIIB non-small-cell lung cancer: study CTRT99/97 by the Bronchial Carcinoma Therapy Group.
Huber RM; Flentje M; Schmidt M; Pöllinger B; Gosse H; Willner J; Ulm K;
J Clin Oncol; 2006 Sep; 24(27):4397-404. PubMed ID: 16983107
[TBL] [Abstract][Full Text] [Related]
49. Extranodal NK/T-cell lymphoma, nasal type, possibly arising from chronic Epstein-Barr virus infection.
Seishima M; Yuge M; Kosugi H; Nagasaka T
Acta Derm Venereol; 2010; 90(1):102-3. PubMed ID: 20107744
[No Abstract] [Full Text] [Related]
50. [Clinical features and prognosis of nasal type NK/T cell lymphoma].
Zhang YJ; Hu WH; Liu H; Cheng EC; Ren ZM; Xia YF; Cui NJ
Zhonghua Zhong Liu Za Zhi; 2006 Jan; 28(1):50-3. PubMed ID: 16737622
[TBL] [Abstract][Full Text] [Related]
51. [Clinical characteristics and treatment of midline nasal and nasal type NK/T cell lymphoma].
Yong W; Zheng W; Zhang Y
Zhonghua Yi Xue Za Zhi; 2001 Jul; 81(13):773-5. PubMed ID: 11798962
[TBL] [Abstract][Full Text] [Related]
52. Concurrent chemoradiotherapy with vinorelbine and a platinum compound followed by consolidation chemotherapy for unresectable stage III non-small cell lung cancer: preliminary results of a phase II study.
Rusu P; Ciuleanu TE; Cernea D; Pelau D; Gaal V; Cebotaru C; Guttman T; Todor N; Ghilezan N
J BUON; 2007; 12(1):33-9. PubMed ID: 17436399
[TBL] [Abstract][Full Text] [Related]
53. Extranodal NK/T-cell lymphoma with cutaneous involvement: 'nasal' vs. 'nasal-type' subgroups--a retrospective study of 18 patients.
Choi YL; Park JH; Namkung JH; Lee JH; Yang JM; Lee ES; Lee DY; Jang KT; Ko YH
Br J Dermatol; 2009 Feb; 160(2):333-7. PubMed ID: 19014396
[TBL] [Abstract][Full Text] [Related]
54. Extranodal nasal type NK/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy.
Lee J; Park YH; Kim WS; Lee SS; Ryoo BY; Yang SH; Park KW; Kang JH; Park JO; Lee SH; Kim K; Jung CW; Park YS; Im YH; Kang WK; Lee MH; Ko YH; Ahn YC; Park K
Eur J Cancer; 2005 Jul; 41(10):1402-8. PubMed ID: 15963893
[TBL] [Abstract][Full Text] [Related]
55. Efficacy of pegaspargase in extra nodal natural killer/T-cell lymphoma nasal type: A case report from China.
Xiong X; Cai Z; Yang J; Shu X
J Cancer Res Ther; 2015; 11(3):665. PubMed ID: 26458696
[TBL] [Abstract][Full Text] [Related]
56. NK/T-cell lymphoma nasal type with an unusual clinical course.
Radochova V; Radocha J; Nova M; Belada D; Slezak R
Indian J Dermatol Venereol Leprol; 2014; 80(6):564-6. PubMed ID: 25382527
[No Abstract] [Full Text] [Related]
57. [The effect of chemo-radiotherapy on the remission and survival in patients with limited stage small cell lung cancer].
Bozóky G; Ruby E; Góhér I; Gábor G; Mohos A; Lengyel M
Orv Hetil; 2005 Jul; 146(27):1433-8. PubMed ID: 16089103
[TBL] [Abstract][Full Text] [Related]
58. Phase III trial of concurrent or sequential adjuvant chemoradiotherapy after conservative surgery for early-stage breast cancer: final results of the ARCOSEIN trial.
Toledano A; Azria D; Garaud P; Fourquet A; Serin D; Bosset JF; Miny-Buffet J; Favre A; Le Floch O; Calais G
J Clin Oncol; 2007 Feb; 25(4):405-10. PubMed ID: 17264336
[TBL] [Abstract][Full Text] [Related]
59. Midline NK/T-cell lymphoma nasal-type: treatment outcome, the effect of L-asparaginase based regimen, and prognostic factors.
Yong W; Zheng W; Zhu J; Zhang Y; Wei Y; Wang X; Lin N; Xie Y; Xu B; Li J
Hematol Oncol; 2006 Mar; 24(1):28-32. PubMed ID: 16323259
[TBL] [Abstract][Full Text] [Related]
60. Postoperative adjuvant concurrent chemoradiotherapy improves survival rates for high-risk, early stage cervical cancer patients.
Ryu HS; Chun M; Chang KH; Chang HJ; Lee JP
Gynecol Oncol; 2005 Feb; 96(2):490-5. PubMed ID: 15661240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
